We are live on ! Find out more
TD Asset Management

TD Asset Management Portfolio holdings

AUM $123B
1-Year Est. Return 34.51%
This Fund
S&P 500
This Quarter Est. Return
+0.28%
1 Year Est. Return
+34.51%
3 Year Est. Return
+98.94%
5 Year Est. Return
+122.3%
10 Year Est. Return
+375.56%
AUM
$96.3B
AUM Growth
-$2.18B
Cap. Flow
-$2.77B
Cap. Flow %
-2.88%
Top 10 Hldgs %
27.83%
Holding
1,579
New
65
Increased
506
Reduced
669
Closed
55

Sector Composition

Rank Sector Weight
1 Financials 20.58%
2 Technology 16.44%
3 Communication Services 9.29%
4 Consumer Discretionary 8.78%
5 Healthcare 8.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SHOO icon
1401
Steven Madden
SHOO
$3.37B
$465K ﹤0.01%
11,581
OBIO icon
1402
Orchestra BioMed
OBIO
$238M
$458K ﹤0.01%
46,339
OFG icon
1403
OFG Bancorp
OFG
$2.23B
$456K ﹤0.01%
18,100
FSBC icon
1404
Five Star Bancorp
FSBC
$1.14B
$450K ﹤0.01%
18,798
+3,900
+26% +$93.7K
ERIE icon
1405
Erie Indemnity
ERIE
$12.7B
$447K ﹤0.01%
2,508
-10
-0.4% -$1.81K
WPCA.WS
1406
DELISTED
Warburg Pincus Capital Corporation I-A Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
WPCA.WS
$446K ﹤0.01%
400,000
ICVX
1407
DELISTED
Icosavax, Inc. Common Stock
ICVX
$445K ﹤0.01%
+15,028
New +$509K
MLTX icon
1408
MoonLake Immunotherapeutics
MLTX
$1.57B
$442K ﹤0.01%
44,766
PRDS
1409
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$442K ﹤0.01%
44,398
BLSA
1410
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$440K ﹤0.01%
44,047
EUCRU
1411
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$435K ﹤0.01%
43,657
SLQT icon
1412
SelectQuote
SLQT
$132M
$430K ﹤0.01%
33,247
-148,200
-82% -$2.23M
CRH icon
1413
CRH
CRH
$63.2B
$429K ﹤0.01%
9,181
-217
-2% -$11K
FSTX
1414
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$428K ﹤0.01%
58,487
MRSN
1415
DELISTED
Mersana Therapeutics
MRSN
$425K ﹤0.01%
1,802
-1,156
-39% -$338K
SQSP
1416
DELISTED
Squarespace, Inc.
SQSP
$421K ﹤0.01%
10,908
-2,032
-16% -$98.2K
REVHW
1417
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Warrant.
REVHW
$421K ﹤0.01%
450,000
KCAC
1418
DELISTED
Kensington Capital Acquisition Corp. II
KCAC
$414K ﹤0.01%
50,000
IMGO
1419
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$410K ﹤0.01%
+20,473
New +$439K
PFHD
1420
DELISTED
Professional Holding Corp. Class A Common stock
PFHD
$408K ﹤0.01%
21,726
CNXN icon
1421
PC Connection
CNXN
$2.11B
$405K ﹤0.01%
9,200
DAWN
1422
DELISTED
Day One Biopharmaceuticals
DAWN
$400K ﹤0.01%
16,856
AGCB
1423
DELISTED
Altimeter Growth Corp 2
AGCB
$396K ﹤0.01%
40,000
-249,591
-86% -$2.49M
NOA
1424
North American Construction
NOA
$369M
$393K ﹤0.01%
+26,990
New +$387K
OPTU
1425
Optimum Communications Inc
OPTU
$298M
$391K ﹤0.01%
18,875
-225,650
-92% -$6.57M

Similar funds

TD Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, TD Asset Management held 1,579 positions worth $96.3B, down 2.2% from $98.5B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

TD Asset Management's Q3 2021 filing shows 65 new, 506 increased, 669 reduced and 55 closed positions. Its largest new stake was GE Aerospace: 1,213,659 shares worth $77.9M. The largest sale was NVIDIA, an estimated $2.33B.

By sector, the portfolio is most concentrated in Financials at 21% of assets, down from 21% a quarter earlier, followed by Technology and Communication Services.

  • TD Asset Management's largest Q3 2021 buy was GE Aerospace: 1,213,659 shares worth $77.9M.
  • TD Asset Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $1.04B increase.
  • TD Asset Management's biggest Q3 2021 reduction was NVIDIA, cutting an estimated $2.33B.
  • TD Asset Management fully exited iShares Russell 2000 ETF in Q3 2021, selling an estimated $583M.
  • TD Asset Management's ten largest holdings make up 28% of its $96.3B portfolio in Q3 2021.
  • TD Asset Management opened 65 new positions and closed 55 in Q3 2021.
  • TD Asset Management's portfolio value fell 2.2% quarter-over-quarter to $96.3B.

Based on TD Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.